文献速递临床试验与 GCP真实世界研究与卫生经济

结构化个体化运动对转移性乳腺癌患者疲乏与生活质量影响的多国随机对照试验设计:EFFECT研究

Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study.
PubMed 文献 · Trials · 2022-07-29

EFFECT研究是一项多国随机对照试验,纳入350例转移性乳腺癌患者,按1:1随机分配至运动组或对照组。运动组接受9个月多模式运动项目,主要结局为基线、3、6(主要终点)和9个月时的生活质量(EORTC QLQ-C30汇总评分)与疲乏(EORTC QLQ-FA12)。研究旨在评估运动项目的(成本)效果,若证实有效,运动应作为转移性乳腺癌标准治疗的一部分提供给患者。

要点

  • EFFECT研究纳入350例转移性乳腺癌患者,随机1:1分为运动组与对照组。
  • 运动组接受9个月多模式运动:前6个月每周2次监督下运动,后3个月替换1次为无监督运动。
  • 主要结局为基线、3、6(主要终点)、9个月的生活质量(EORTC QLQ-C30汇总评分)与疲乏(EORTC QLQ-FA12)。

核心结论

  • 该大型随机对照试验将为转移性乳腺癌治疗期间运动的(成本)效果提供证据;若证实(成本)有效,运动应作为标准治疗的一部分提供给转移性乳腺癌患者。

研究设计与样本

  • 多国随机对照试验,纳入350例转移性乳腺癌患者,按1:1随机分配至运动组或对照组。
  • 运动组接受9个月多模式运动项目:前6个月每周2次在运动专业人员监督下运动;此后3个月将1次监督下运动替换为1次无监督运动;其余天数建议每日身体活动≥30分钟,并辅以活动追踪器和运动应用程序支持。
  • 对照组接受标准医疗照护、一般书面身体活动建议和活动追踪器,但不接受结构化运动项目。
  • 主要结局在基线、3、6(主要终点)和9个月评估;次要结局包括体能、身体表现、身体活动、焦虑、抑郁、疼痛、睡眠问题、人体测量数据、身体成分和血液标志物;探索性结局包括工作生活质量、肌肉厚度、尿失禁、疾病进展和生存;同时评估运动项目的成本效果;干预期间监测依从性和安全性。
  • 试验注册:ClinicalTrials.gov NCT04120298,注册日期2019年10月9日。

临床怎么用

  • 作者认为,若证实(成本)有效,运动应作为标准治疗的一部分提供给转移性乳腺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with metastatic breast cancer experience cancer- and treatment-related side effects that impair activities of daily living and negatively affect the quality of life. There is a need for interventions that improve quality of life by alleviating fatigue and other side effects during palliative cancer treatment. Beneficial effects of exercise have been observed in the curative setting, but, to date, comparable evidence in patients with metastatic breast cancer is lacking. The aim of this study is to assess the effects of a structured and individualized 9-month exercise intervention in patients with metastatic breast cancer on quality of life, fatigue, and other cancer- and treatment-related side effects. METHODS: The EFFECT study is a multinational, randomized controlled trial including 350 patients with metastatic breast cancer. Participants are randomly allocated (1:1) to an exercise or control group. The exercise group participates in a 9-month multimodal exercise program, starting with a 6-month period where participants exercise twice a week under the supervision of an exercise professional. After completing this 6-month period, one supervised session is replaced by one unsupervised session for 3 months. In addition, participants are instructed to be physically active for ≥30 min/day on all remaining days of the week, while being supported by an activity tracker and exercise app. Participants allocated to the control group receive standard medical care, general written physical activity advice, and an activity tracker, but no structured exercise program. The primary outcomes are quality of life (EORTC QLQ-C30, summary score) and fatigue (EORTC QLQ-FA12), assessed at baseline, 3, 6 (primary endpoint), and 9 months post-baseline. Secondary outcomes include physical fitness, physical performance, physical activity, anxiety, depression, pain, sleep problems, anthropometric data, body composition, and blood markers. Exploratory outcomes include quality of working life, muscle thickness, urinary incontinence, disease progression, and survival. Additionally, the cost-effectiveness of the exercise program is assessed. Adherence and safety are monitored throughout the intervention period. DISCUSSION: This large randomized controlled trial will provide evidence regarding the (cost-) effectiveness of exercise during treatment of metastatic breast cancer. If proven (cost-)effective, exercise should be offered to patients with metastatic breast cancer as part of standard care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04120298 . Registered on October 9, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hiensch AE, Monninkhof EM, Schmidt ME, et al. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study. Trials. 2022. PMID: 35906659. doi:10.1186/s13063-022-06556-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。